A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

ClinicalTrials.gov ID: NCT04026997

Public ClinicalTrials.gov record NCT04026997. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.

Study identification

NCT ID: NCT04026997
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: CinDome Pharma, Inc.; Industry
Enrollment: 72 participants

Conditions and interventions

Conditions

Gastroparesis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 11, 2019 (Actual)
Primary completion: Dec 17, 2020 (Actual)
Completion: Dec 17, 2020 (Actual)
Last update posted: Mar 25, 2026

2019 – 2020

United States locations

U.S. sites: 19
U.S. states: 16
U.S. cities: 18

Facility	City	State	ZIP	Site status
Research Site 101	Chula Vista	California	91910	—
Research Site 114	Jacksonville	Florida	32224	—
Research Site 117	Miami	Florida	33134	—
Research Site 118	Miami	Florida	33183	—
Research Site 111	Atlanta	Georgia	30322	—
Research Site 110	Kansas City	Kansas	66045	—
Research Site 103	Louisville	Kentucky	40202	—
Research Site 112	Marrero	Louisiana	70072	—
Research Site 104	Monroe	Louisiana	71201	—
Research Site 102	Boston	Massachusetts	02215	—
Research Site 121	Omaha	Nebraska	68134	—
Research Site 113	Las Vegas	Nevada	89123	—
Research Site 109	Great Neck	New York	11023	—
Research Site 120	Winston-Salem	North Carolina	27103	—
Research Site 105	Tulsa	Oklahoma	74104	—
Research Site 106	Philadelphia	Pennsylvania	19140	—
Research Site 119	Summerville	South Carolina	29485	—
Research Site 115	Rapid City	South Dakota	57702	—
Research Site 107	Jackson	Tennessee	38305	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04026997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 25, 2026 · Synced Nov 9, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04026997 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →